---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-250677"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:13:45.874259+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neumora starts Phase 1 study of second M4 PAM, NMRA-898; no convulsions in preclinical

## Summary
- Initiated Phase 1 SAD/MAD study of NMRA-898, an M4 positive allosteric modulator for schizophrenia and neuropsychiatric disorders.
- NMRA-898 is structurally distinct from NMRA-861 (Phase 1 started July 2025); both may offer best-in-class pharmacology.
- No convulsions observed in preclinical studies across multiple species, including rabbits.
- Neumora expects to provide a comprehensive M4 franchise update by mid-2026.

## SEC filing metadata
- accession: 0001193125-25-250677
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525250677/0001193125-25-250677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525250677/nmra-20251027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-250677
- JSON: https://secwatch.observer/filing/0001193125-25-250677.json
- Plain text: https://secwatch.observer/filing/0001193125-25-250677.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.